Stockscreener 앱 받기
1.98
5.88%
0.11
전일 마감가:
$1.87
열려 있는:
$1.94
하루 거래량:
1.98M
Relative Volume:
1.27
시가총액:
$62.48M
수익:
-
순이익/손실:
$-69.00M
주가수익비율:
-0.7122
EPS:
-2.78
순현금흐름:
$-55.26M
1주 성능:
+13.14%
1개월 성능:
-18.18%
6개월 성능:
+52.31%
1년 성능:
-64.32%
1일 변동 폭
$1.90
$2.04
1주일 범위
$1.5701
$2.04
52주 변동 폭
$1.05
$8.00
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
명칭
Acrivon Therapeutics Inc
전화
617-207-8979
주소
480 ARSENAL WAY, SUITE 100, WATERTOWN
ACRV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.98 | 59.01M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-05 | 재개 | Piper Sandler | Overweight |
| 2025-01-31 | 개시 | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | 개시 | JMP Securities | Mkt Outperform |
| 2023-12-15 | 재개 | Jefferies | Buy |
| 2023-10-05 | 개시 | Maxim Group | Buy |
| 2023-06-02 | 개시 | Oppenheimer | Outperform |
| 2023-05-08 | 개시 | BMO Capital Markets | Outperform |
| 2023-04-27 | 개시 | Ladenburg Thalmann | Buy |
| 2023-04-20 | 개시 | H.C. Wainwright | Buy |
| 2022-12-12 | 개시 | Cowen | Outperform |
| 2022-12-12 | 개시 | Jefferies | Buy |
| 2022-12-12 | 개시 | Piper Sandler | Overweight |
모두보기
Acrivon Therapeutics Inc 주식(ACRV)의 최신 뉴스
Insider Spends US$82k Buying More Shares In Acrivon Therapeutics - simplywall.st
Co-Founder of Acrivon Therapeutics Peter Blume-Jensen Buys 2.6% More Shares - Yahoo Finance
Price Action: Can Acrivon Therapeutics Inc ride the EV waveDay Trade & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Acrivon Therapeutics CEO Blume-Jensen buys $82k in shares By Investing.com - Investing.com Nigeria
Top Brass Doubles Down on Acrivon With Bold Insider Buying Spree - TipRanks
Acrivon Therapeutics CEO Blume-Jensen buys $82k in shares - Investing.com
Volume Report: Is BMLPRJs ROE strong enoughEarnings Risk Report & Risk Managed Investment Signals - baoquankhu1.vn
Aug Decliners: Can Acrivon Therapeutics Inc ride the EV waveCEO Change & Smart Allocation Stock Tips - baoquankhu1.vn
Top Acrivon Executive Makes Bold Insider Move That Signals Growing Confidence - TipRanks
Insider Buying: Eric Devroe Acquires 10,000 Shares of Acrivon Th - GuruFocus
Acrivon Therapeutics COO Devroe buys $17k in shares By Investing.com - Investing.com UK
Acrivon Therapeutics COO Devroe buys $17k in shares - Investing.com
Acrivon Therapeutics (NASDAQ:ACRV) COO Purchases $17,200.00 in Stock - MarketBeat
U.S. Initial Jobless Claims Rise to 208,000, Mixed Market Reaction - Intellectia AI
Movement Recap: What risks investors should watch in Acrivon Therapeutics Inc stockMarket Performance Summary & Safe Entry Momentum Stock Tips - Bộ Nội Vụ
Growth Value: Can Acrivon Therapeutics Inc expand into new marketsJuly 2025 Momentum & Entry Point Confirmation Signals - baoquankhu1.vn
Acrivon Therapeutics Spotlights ACR368 Endometrial Cancer Data, Adds Serous Arm 3 and FDA Phase 3 Plan - MarketBeat
Acrivon Therapeutics (NASDAQ:ACRV) Stock Rating Lowered by Wall Street Zen - MarketBeat
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data By Investing.com - Investing.com South Africa
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data - Investing.com Australia
Acrivon reports 52% response rate in serous endometrial cancer trial By Investing.com - Investing.com Nigeria
How Acrivon Therapeutics Inc. stock compares to market leadersM&A Rumor & Long-Term Safe Investment Plans - Улправда
What is the fair value of Acrivon Therapeutics Inc. stock nowJuly 2025 Sector Moves & Verified Chart Pattern Signals - Улправда
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - Sahm
Why Acrivon Therapeutics Inc. stock could rally in 2025Treasury Yields & Community Consensus Picks - Улправда
Treasury Yields: Can Acrivon Therapeutics Inc. stock resist market sell offsWeekly Trade Summary & High Accuracy Investment Entry Signals - Улправда
Acrivon Therapeutics Inc. (ACRV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why Acrivon Therapeutics Inc. stock remains a top recommendationInflation Watch & Fast Moving Market Watchlists - Улправда
Why retail investors pile into Acrivon Therapeutics Inc. stockSwing Trade & Long-Term Growth Stock Strategies - Улправда
Small-Cap Acrivon Showcases Tumor Reduction and Clinical Advancement in Major Trials, Shares Decline - Bitget
Acrivon Therapeutics Inc.: Rise or Retreat? - StocksToTrade
Acrivon Stock Sinks 29% Despite Positive Phase 2b Endometrial Cancer Data - Nasdaq
Aug Gainers: What is the fair value of Acrivon Therapeutics Inc. stock now2025 Key Lessons & High Accuracy Trade Signal Alerts - Улправда
Focused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating - TipRanks
Exit Recap: Why retail investors pile into Acrivon Therapeutics Inc. stockOptions Play & Safe Entry Point Alerts - ulpravda.ru
Why Is Acrivon Therapeutics Stock Falling Today?Acrivon Therapeutics (NASDAQ:ACRV) - Benzinga
Dow Jumps Over 250 Points; US Initial Jobless Claims Increase - Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
What momentum indicators show for Acrivon Therapeutics Inc. stockQuarterly Profit Review & Verified Short-Term Plans - ulpravda.ru
Acrivon Therapeutics announces progress across pipeline - TipRanks
Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings - Benzinga
Acrivon Therapeutics stock plunges after mixed cancer trial results By Investing.com - Investing.com South Africa
Acrivon Therapeutics stock plunges after mixed cancer trial results - Investing.com
Is Acrivon Therapeutics Inc. stock overvalued by current metrics2025 Retail Activity & AI Enhanced Trading Alerts - Улправда
Acrivon Showcases Promising Phase 2b Oncology Data Update - TipRanks
Acrivon Therapeutics Stock (ACRV) Opinions on Clinical Data Release - Quiver Quantitative
Acrivon's ACR-368 Shows 52% Response Rate In Endometrial Cancer, Expands Trial To Europe - Nasdaq
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data - TipRanks
New cancer drugs show tumor shrinkage in early trials - Stock Titan
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b - GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Acrivon Therapeutics Inc (ACRV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Acrivon Therapeutics Inc 주식 (ACRV) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Levy Adam D. | Chief Financial Officer |
Jan 14 '26 |
Buy |
1.70 |
8,832 |
14,999 |
20,983 |
| Devroe Eric | Chief Operating Officer |
Jan 13 '26 |
Buy |
1.72 |
10,000 |
17,218 |
75,308 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 30 '25 |
Sale |
1.41 |
437,881 |
617,412 |
3,403,025 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
May 01 '25 |
Sale |
1.34 |
298,886 |
400,507 |
3,104,139 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 25 '25 |
Sale |
1.95 |
1,054,669 |
2,056,605 |
4,306,189 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 29 '25 |
Sale |
1.41 |
250,000 |
352,500 |
3,840,906 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 28 '25 |
Sale |
1.56 |
215,283 |
335,841 |
4,090,906 |
4.73%
0.92%
자본화:
|
볼륨(24시간):